DexCom, Inc. (DXCM) EPS Diluted: 2.09
Is DexCom, Inc.’s EPS diluted high or low?
DexCom, Inc.'s EPS diluted of 2.09 is 70% above its 5-year average of 1.23, near the high end of its 5-year range (0.51–2.09).
The EPS diluted for DexCom, Inc. (DXCM) is 2.09. It is above its 12-month average by 19.09% (1.75).
DXCM EPS Diluted Chart
DXCM Average EPS Diluted Chart
DXCM Current vs Average EPS Diluted Chart
DXCM EPS Diluted Metrics
EPS DILUTED
2.09
EPS DILUTED AVG TTM
1.75
EPS DILUTED AVG 3Y
1.40
EPS DILUTED AVG 5Y
1.23
EPS DILUTED AVG 10Y
0.62
EPS DILUTED AVG 15Y
0.37
EPS DILUTED AVG 20Y
0.19
CURRENT VS TTM AVG
+19.09%
CURRENT VS 3Y AVG
+49.02%
CURRENT VS 5Y AVG
+69.69%
CURRENT VS 10Y AVG
+239.59%
CURRENT VS 15Y AVG
+458.68%
CURRENT VS 20Y AVG
+1006.80%
DexCom, Inc. EPS Diluted Formula & Definition
EPS Diluted includes the effect of convertible securities, options, and other potential shares. Compare it with basic EPS to see the impact of potential dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
DexCom, Inc. EPS Diluted FAQ
- What is the EPS diluted for DexCom, Inc. (DXCM)?
- The EPS diluted for DXCM stock is 2.09.
- Is DexCom, Inc.'s EPS diluted high or low?
- DexCom, Inc.'s EPS diluted of 2.09 is 70% above its 5-year average of 1.23, near the high end of its 5-year range (0.51–2.09).
- What is the TTM average EPS diluted for DexCom, Inc. (DXCM)?
- The TTM average EPS diluted for DXCM stock is 1.75.
- What is the 3Y average EPS diluted for DexCom, Inc. (DXCM)?
- The 3Y average EPS diluted for DXCM stock is 1.40.
- What is the 5Y average EPS diluted for DexCom, Inc. (DXCM)?
- The 5Y average EPS diluted for DXCM stock is 1.23.
- What is the 10Y average EPS diluted for DexCom, Inc. (DXCM)?
- The 10Y average EPS diluted for DXCM stock is 0.62.
- What is the 15Y average EPS diluted for DexCom, Inc. (DXCM)?
- The 15Y average EPS diluted for DXCM stock is 0.37.
- What is the 20Y average EPS diluted for DexCom, Inc. (DXCM)?
- The 20Y average EPS diluted for DXCM stock is 0.19.
DexCom, Inc. EPS Diluted History
| DATE | EPS DILUTED |
|---|---|
| 2025-12-31 | 2.09 |
| 2024-12-31 | 1.42 |
| 2023-12-31 | 1.30 |
| 2022-12-31 | 0.80 |
| 2021-12-31 | 0.51 |
| 2020-12-31 | 1.27 |
| 2019-12-31 | 0.27 |
| 2018-12-31 | -0.36 |
| 2017-12-31 | -0.15 |
| 2016-12-31 | -0.20 |
| 2015-12-31 | -0.18 |
| 2014-12-31 | -0.07 |
| 2013-12-31 | -0.10 |
| 2012-12-31 | -0.20 |
| 2011-12-31 | -0.17 |
| 2010-12-31 | -0.24 |
| 2009-12-31 | -0.30 |
| 2008-12-31 | -0.47 |
| 2007-12-31 | -0.41 |
| 2006-12-31 | -0.43 |
| 2005-12-31 | -0.41 |
| 2004-12-31 | -1.53 |
| 2003-12-31 | -1.14 |
| 2002-12-31 | -0.94 |
| 2001-12-31 | -0.83 |
| 2000-12-31 | -0.57 |
Related Metrics
About DexCom, Inc.
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Jacob Steven Leach